Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
DexCom, Inc. stock logo
DXCM
DexCom
$128.37
+1.4%
$132.11
$74.75
$142.00
$51.05B1.232.99 million shs1.78 million shs
NovoCure Limited stock logo
NVCR
NovoCure
$14.78
+4.2%
$14.21
$10.87
$83.60
$1.53B0.51.09 million shs1.15 million shs
Insulet Co. stock logo
PODD
Insulet
$174.43
+0.6%
$169.57
$125.82
$335.91
$12.14B1712,105 shs614,615 shs
ResMed Inc. stock logo
RMD
ResMed
$216.98
-0.5%
$189.86
$132.24
$237.26
$32.05B0.641.34 million shs640,837 shs
Teleflex Incorporated stock logo
TFX
Teleflex
$203.01
+2.2%
$217.97
$177.63
$262.97
$9.36B1.13322,570 shs508,387 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
DexCom, Inc. stock logo
DXCM
DexCom
+1.36%+3.24%-7.32%+6.13%+9.42%
NovoCure Limited stock logo
NVCR
NovoCure
+4.16%+16.98%+2.50%+4.82%-77.59%
Insulet Co. stock logo
PODD
Insulet
+0.58%+4.96%+5.80%-10.10%-45.66%
ResMed Inc. stock logo
RMD
ResMed
-0.54%-0.50%+16.63%+13.09%-8.37%
Teleflex Incorporated stock logo
TFX
Teleflex
+2.13%-1.79%-5.46%-17.39%-25.40%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
DexCom, Inc. stock logo
DXCM
DexCom
4.9634 of 5 stars
3.55.00.04.72.62.53.1
NovoCure Limited stock logo
NVCR
NovoCure
4.1532 of 5 stars
4.31.00.04.52.32.50.0
Insulet Co. stock logo
PODD
Insulet
4.8991 of 5 stars
3.45.00.04.92.80.83.1
ResMed Inc. stock logo
RMD
ResMed
4.5329 of 5 stars
2.41.03.34.53.21.72.5
Teleflex Incorporated stock logo
TFX
Teleflex
4.9236 of 5 stars
3.35.01.73.92.52.52.5

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
DexCom, Inc. stock logo
DXCM
DexCom
2.93
Moderate Buy$141.6710.36% Upside
NovoCure Limited stock logo
NVCR
NovoCure
2.56
Moderate Buy$30.88108.90% Upside
Insulet Co. stock logo
PODD
Insulet
2.80
Moderate Buy$243.2139.43% Upside
ResMed Inc. stock logo
RMD
ResMed
2.70
Moderate Buy$202.80-6.54% Downside
Teleflex Incorporated stock logo
TFX
Teleflex
2.67
Moderate Buy$261.7528.93% Upside

Current Analyst Ratings

Latest TFX, PODD, RMD, NVCR, and DXCM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$240.00 ➝ $219.00
5/3/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold
5/2/2024
NovoCure Limited stock logo
NVCR
NovoCure
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral$21.00
5/2/2024
NovoCure Limited stock logo
NVCR
NovoCure
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$24.00 ➝ $22.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetStrong-Buy ➝ Strong-Buy$151.00 ➝ $160.00
4/26/2024
DexCom, Inc. stock logo
DXCM
DexCom
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$144.00 ➝ $145.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$205.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Perform ➝ Sector Perform$187.00 ➝ $200.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$227.00 ➝ $238.00
4/26/2024
ResMed Inc. stock logo
RMD
ResMed
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$224.00 ➝ $236.00
4/10/2024
DexCom, Inc. stock logo
DXCM
DexCom
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$153.00 ➝ $163.00
(Data available from 5/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
DexCom, Inc. stock logo
DXCM
DexCom
$3.62B14.09$2.10 per share61.21$5.65 per share22.72
NovoCure Limited stock logo
NVCR
NovoCure
$509.34M3.12N/AN/A$3.39 per share4.36
Insulet Co. stock logo
PODD
Insulet
$1.70B7.20$3.82 per share45.70$10.49 per share16.63
ResMed Inc. stock logo
RMD
ResMed
$4.22B7.55$7.77 per share27.94$31.52 per share6.88
Teleflex Incorporated stock logo
TFX
Teleflex
$2.97B3.21$19.24 per share10.55$95.61 per share2.12

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
DexCom, Inc. stock logo
DXCM
DexCom
$541.50M$1.5582.8257.312.1616.82%31.01%10.29%7/25/2024 (Estimated)
NovoCure Limited stock logo
NVCR
NovoCure
-$207.04M-$1.81N/AN/AN/A-36.67%-49.34%-16.75%7/25/2024 (Estimated)
Insulet Co. stock logo
PODD
Insulet
$206.30M$2.9159.9445.073.1212.16%32.19%7.93%5/9/2024 (Confirmed)
ResMed Inc. stock logo
RMD
ResMed
$897.56M$6.5133.3325.292.7020.91%24.43%15.70%8/1/2024 (Estimated)
Teleflex Incorporated stock logo
TFX
Teleflex
$356.33M$6.2332.5913.361.909.82%14.78%8.79%8/1/2024 (Estimated)

Latest TFX, PODD, RMD, NVCR, and DXCM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Insulet Co. stock logo
PODD
Insulet
$0.39N/A-$0.39N/AN/AN/A  
5/2/2024Q1 2024
NovoCure Limited stock logo
NVCR
NovoCure
-$0.43-$0.36+$0.07-$0.36$131.44 million$138.50 million      
5/2/2024Q1 2024
Teleflex Incorporated stock logo
TFX
Teleflex
$3.07$3.21+$0.14$6.10$726.85 million$737.80 million      
4/25/2024Q1 2024
DexCom, Inc. stock logo
DXCM
DexCom
$0.27$0.32+$0.05$0.28$911.20 million$921.00 million    
4/25/2024Q3 24
ResMed Inc. stock logo
RMD
ResMed
$1.91$2.13+$0.22$2.22$1.17 billion$1.20 billion    
2/22/2024Q4 2023
NovoCure Limited stock logo
NVCR
NovoCure
-$0.53-$0.45+$0.08-$0.45$133.80 million$133.80 million      
2/22/2024Q4 2023
Insulet Co. stock logo
PODD
Insulet
$0.67$1.40+$0.73$1.36$461.26 million$509.80 million    
2/22/2024Q4 23
Teleflex Incorporated stock logo
TFX
Teleflex
$3.26$3.38+$0.12$6.10$769.01 million$773.90 million      
2/8/2024Q4 2023
DexCom, Inc. stock logo
DXCM
DexCom
$0.43$0.50+$0.07$0.38$1.02 billion$1.03 billion      

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
DexCom, Inc. stock logo
DXCM
DexCom
N/AN/AN/AN/AN/A
NovoCure Limited stock logo
NVCR
NovoCure
N/AN/AN/AN/AN/A
Insulet Co. stock logo
PODD
Insulet
N/AN/AN/AN/AN/A
ResMed Inc. stock logo
RMD
ResMed
$1.920.88%+5.66%29.49%12 Years
Teleflex Incorporated stock logo
TFX
Teleflex
$1.360.67%N/A21.83%N/A

Latest TFX, PODD, RMD, NVCR, and DXCM Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/25/2024
ResMed Inc. stock logo
RMD
ResMed
Quarterly$0.480.88%5/8/20245/9/20246/13/2024
2/22/2024
Teleflex Incorporated stock logo
TFX
Teleflex
Quarterly$0.340.57%2/29/20243/1/20243/15/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
DexCom, Inc. stock logo
DXCM
DexCom
1.08
2.90
2.53
NovoCure Limited stock logo
NVCR
NovoCure
1.57
5.78
5.56
Insulet Co. stock logo
PODD
Insulet
1.86
3.51
2.62
ResMed Inc. stock logo
RMD
ResMed
0.22
3.04
1.97
Teleflex Incorporated stock logo
TFX
Teleflex
0.37
2.51
1.29

Ownership

Institutional Ownership

CompanyInstitutional Ownership
DexCom, Inc. stock logo
DXCM
DexCom
97.75%
NovoCure Limited stock logo
NVCR
NovoCure
84.61%
Insulet Co. stock logo
PODD
Insulet
N/A
ResMed Inc. stock logo
RMD
ResMed
54.98%
Teleflex Incorporated stock logo
TFX
Teleflex
95.62%

Insider Ownership

CompanyInsider Ownership
DexCom, Inc. stock logo
DXCM
DexCom
0.41%
NovoCure Limited stock logo
NVCR
NovoCure
5.67%
Insulet Co. stock logo
PODD
Insulet
0.47%
ResMed Inc. stock logo
RMD
ResMed
1.21%
Teleflex Incorporated stock logo
TFX
Teleflex
1.43%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
DexCom, Inc. stock logo
DXCM
DexCom
9,600397.68 million396.05 millionOptionable
NovoCure Limited stock logo
NVCR
NovoCure
1,453107.61 million101.51 millionOptionable
Insulet Co. stock logo
PODD
Insulet
3,00070.02 million69.69 millionOptionable
ResMed Inc. stock logo
RMD
ResMed
10,140146.91 million145.13 millionOptionable
Teleflex Incorporated stock logo
TFX
Teleflex
14,50047.10 million46.43 millionOptionable

TFX, PODD, RMD, NVCR, and DXCM Headlines

SourceHeadline
Teleflex Incorporated (NYSE:TFX) Q1 2024 Earnings Call TranscriptTeleflex Incorporated (NYSE:TFX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - May 3 at 9:01 PM
Teleflex (NYSE:TFX) Updates FY 2024 Earnings GuidanceTeleflex (NYSE:TFX) Updates FY 2024 Earnings Guidance
marketbeat.com - May 3 at 7:23 PM
Teleflex (TFX) Q1 Earnings Beat Estimates, Margins RiseTeleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise
zacks.com - May 3 at 1:16 PM
Teleflex Inc (TFX) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Revenue and ...Teleflex Inc (TFX) Q1 2024 Earnings Call Transcript Highlights: Strong Start with Revenue and ...
finance.yahoo.com - May 3 at 9:32 AM
Teleflex First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsTeleflex First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
finance.yahoo.com - May 3 at 9:32 AM
Teleflex (NYSE:TFX) PT Lowered to $219.00 at Truist FinancialTeleflex (NYSE:TFX) PT Lowered to $219.00 at Truist Financial
marketbeat.com - May 3 at 9:00 AM
Teleflexs (TFX) "Hold" Rating Reiterated at Needham & Company LLCTeleflex's (TFX) "Hold" Rating Reiterated at Needham & Company LLC
marketbeat.com - May 3 at 8:38 AM
How Is The Market Feeling About Teleflex?How Is The Market Feeling About Teleflex?
benzinga.com - May 2 at 4:05 PM
Teleflex beats quarterly profit estimates on healthy demand for medical devicesTeleflex beats quarterly profit estimates on healthy demand for medical devices
reuters.com - May 2 at 11:04 AM
Teleflex Q1 Results Top Estimates: Boosts FY24 Adj. EPS OutlookTeleflex Q1 Results Top Estimates: Boosts FY24 Adj. EPS Outlook
markets.businessinsider.com - May 2 at 11:04 AM
TFX Stock Earnings: Teleflex Beats EPS, Beats Revenue for Q1 2024TFX Stock Earnings: Teleflex Beats EPS, Beats Revenue for Q1 2024
msn.com - May 2 at 11:04 AM
Teleflex Inc (TFX) Q1 Earnings: Adjusted EPS Surpasses Estimates Amidst Revenue GrowthTeleflex Inc (TFX) Q1 Earnings: Adjusted EPS Surpasses Estimates Amidst Revenue Growth
finance.yahoo.com - May 2 at 11:04 AM
Teleflex (NYSE:TFX) Updates FY24 Earnings GuidanceTeleflex (NYSE:TFX) Updates FY24 Earnings Guidance
marketbeat.com - May 2 at 10:38 AM
Compared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key MetricsCompared to Estimates, Teleflex (TFX) Q1 Earnings: A Look at Key Metrics
zacks.com - May 2 at 10:36 AM
Teleflex (TFX) Tops Q1 Earnings and Revenue EstimatesTeleflex (TFX) Tops Q1 Earnings and Revenue Estimates
zacks.com - May 2 at 8:46 AM
Teleflex Incorporated 2024 Q1 - Results - Earnings Call PresentationTeleflex Incorporated 2024 Q1 - Results - Earnings Call Presentation
seekingalpha.com - May 2 at 8:05 AM
Teleflex Reports First Quarter Financial Results and Full Year 2024 OutlookTeleflex Reports First Quarter Financial Results and Full Year 2024 Outlook
globenewswire.com - May 2 at 6:30 AM
New York State Common Retirement Fund Has $9.12 Million Holdings in Teleflex Incorporated (NYSE:TFX)New York State Common Retirement Fund Has $9.12 Million Holdings in Teleflex Incorporated (NYSE:TFX)
marketbeat.com - May 2 at 4:59 AM
Heres what to expect from Teleflexs earnings reportHere's what to expect from Teleflex's earnings report
markets.businessinsider.com - May 1 at 11:38 PM
Teleflex announces limited launch of Wattson Temporary Pacing GuidewireTeleflex announces limited launch of Wattson Temporary Pacing Guidewire
massdevice.com - May 1 at 1:31 PM
Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?Will These 5 MedTech Stocks Beat Forecasts This Earnings Season?
zacks.com - May 1 at 12:46 PM
Ahead of Teleflex (TFX) Q1 Earnings: Get Ready With Wall Street Estimates for Key MetricsAhead of Teleflex (TFX) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
zacks.com - May 1 at 10:21 AM
Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the ...Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the ...
eagletribune.com - May 1 at 8:30 AM
Teleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual MeetingTeleflex Announces Multiple Clinical and Real-World Evidence Studies to Be Highlighted at the 2024 American Urological Association Annual Meeting
globenewswire.com - May 1 at 6:30 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

DexCom logo

DexCom

NASDAQ:DXCM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.
NovoCure logo

NovoCure

NASDAQ:NVCR
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Insulet logo

Insulet

NASDAQ:PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
ResMed logo

ResMed

NYSE:RMD
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force. The company was founded in 1989 and is headquartered in San Diego, California.
Teleflex logo

Teleflex

NYSE:TFX
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site. It also offers interventional products, which consists of various coronary catheters, structural heart support devices, and peripheral intervention and mechanical circulatory support platform that are used by interventional cardiologists and radiologists, and vascular surgeons; and Arrow branded pumps and catheters, Guideline, Turnpike, and Trapliner catheters, the Manta Vascular Closure, and Arrow Oncontrol devices. The company provides anesthesia products, such as airway and pain management products to support hospital, emergency medicine, and military channels; and surgical products, including metal and polymer ligation clips, and fascial closure surgical systems that are used in laparoscopic surgical procedures, percutaneous surgical systems, and other surgical instruments. It also offers interventional urology products comprising the UroLift System, an invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia; respiratory products, including oxygen and aerosol therapies, spirometry, and ventilation management products for use in various care settings; urology products, such as catheters, urine collectors, and catheterization accessories and products for operative endourology; and bladder management services. The company serves hospitals and healthcare providers, medical device manufacturers, and home care markets. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.